P305 Neoadjuvant chemotherapy should also be considered for lobular breast cancer

Neoadjuvant Chemotherapy for Breast Cancer

Staphylococcus lugdunensis; a pathogen that should be considered in Iran

Background: Staphylococcus lugdunensis is Gram-positive cocci of the staphylococcaceae family. S. lugdunensis despite having a clotting factor (wall coagulase), was classified in the coagulase negative staphylococcus group (CoNS) for lack of free coagulase. Although this bacterium is part of the human normal flora, in terms of virulence, S. lugdunensis is in second place after S. aureus. S. lug...

Rethinking neoadjuvant chemotherapy for breast cancer.

Jayant S Vaidya professor of surgery and oncology and consultant breast cancer surgeon 1 , Samuele Massarut director of oncological breast surgery , Hrisheekesh J Vaidya medical student , Emma C Alexander medical student , Thomas Richards consultant in clinical oncology , Jochem A Caris senior breast surgery registrar 7 , Bhawna Sirohi consultant medical oncologist , Jeffrey S Tobias professor ...

Neoadjuvant chemotherapy for operable breast cancer.

Adjuvant systemic chemotherapy has been shown to prolong survival in all subsets of patients with breast cancer. In addition, among patients with locally advanced breast cancer, neoadjuvant orpreoperative chemotherapy has improved the ability to perform breast-conserving therapy. This observation, combined with multiple preclinical hypotheses and the results of laboratory studies, has prompted ...

Neoadjuvant Chemotherapy for Breast Cancer: Unanswered Questions